Podcasts about Oncology

In 1987, Mary P. Lovato, a member of Kewa Pueblo in New Mexico, was diagnosed with acute leukemia. To receive a bone marrow transplant, she had to travel more than 800 miles from home because specialized cancer care was unavailable through the Indian Health Service. When she returned, she discovered another obstacle: many in her community feared cancer so deeply that they avoided speaking about it altogether.This episode examines how cancer survivorship exposed profound inequities in the American healthcare system. Long before health equity became a national priority, advocates from underserved communities were confronting disparities rooted in geography, poverty, racism, language, underfunded healthcare systems, and historical mistrust of medical institutions. Their work demonstrated that scientific advances alone cannot improve survival if patients cannot reach, afford, or trust the care available to them.The story follows pioneers including Mary P. Lovato, who built the first national Native-led cancer support and education program for Indigenous communities, and Maimah Karmo, founder of the Tigerlily Foundation, whose breast cancer diagnosis inspired a movement to improve early detection, clinical trial participation, and representation for Black women. Their advocacy challenged longstanding barriers to culturally competent care while highlighting persistent inequities in access to screening, fertility preservation, navigation, and innovative treatments.The episode also explores why diversity in clinical research matters. For decades, many cancer clinical trials disproportionately enrolled White patients, limiting both access to promising therapies and the scientific understanding of how treatments perform across different populations. Researchers, patient advocates, and community leaders responded by redesigning outreach, improving patient navigation, reducing logistical barriers, and insisting that affected communities help shape the research itself.Cancer survivorship cannot be measured solely by scientific breakthroughs. It also depends on whether every patient has a meaningful opportunity to benefit from them. The pursuit of health equity remains one of the defining challenges and enduring responsibilities of modern oncology.RELATED LINKSNational Cancer Institute | Cancer Health Disparities⁠Indian Health Service⁠Tigerlily Foundation⁠National Cancer Institute | Cancer Clinical Trials⁠American Indian Cancer Foundation⁠Abramson Cancer Center | University of Pennsylvania⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Ayesha and Andrew discuss the September 2, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Orthopaedic Essentials, Shoulder, Oncology, Spine, Rehabilitation, Basic Science, Knee, Ethics Chapters (00:00:02) - Your Cases On Hold(00:03:12) - The New in Orthopedic Rehabilitation: Orthobiologics(00:05:32) - VEGF Inhibitor reinitiation and wound complications in(00:14:13) - VEGF Inhibitors and wound complications(00:22:59) - Reversible Shoulder Arthroplasty with an Allograft(00:27:19) - Post-operative complications of iliac crest bone grafting(00:29:08) - The Essential Surgical Techniques article(00:33:54) - Case On Hold(00:34:21) - Prevascularized Bone marrow Stem Cell Sheets Promote T(00:44:07) - Oh, Well...

Metastatic breast cancer cannot be cured but it can be treated. Treatment focuses on disease management while maintaining the best possible quality of life. The unfortunate reality is that a treatment will only work for so long, then another one is needed. Joining us today are two women living with metastatic breast cancer who are sharing their experiences, living one treatment to the next. They are tireless advocates for research and the breakthroughs that will ensure their next treatment is available, when they need it. They're sharing how they live life to the fullest and manage their day-to-day care. Key Takeaways It's important to find hope while living treatment to treatment Recognize the physical and emotional toll of treatment, even when you look well Advocate for research, clinical trials, and discoveries that lead to better treatments Live in the present, prioritize quality of life, and give yourself grace Chapters 00:00 — Living with metastatic breast cancer 03:25 — The reality of treatment after treatment 07:45 — The emotional weight of uncertainty 13:23 — Why metastatic breast cancer research matters 26:34 — Living in the present and finding hope Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To Cancer⁠Katie Couric Media⁠Dempsey Center⁠American Association for Cancer Research⁠National Cancer Institute⁠Dana-Farber Cancer Institute | Adult Survivorship Program⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send us Fan MailAre you sharing your microbiome with your roommate? What about your romantic partner?In this episode of Causes or Cures, Dr. Eeks talks with microbiome researcher Dr. Nicola Segata about new research showing that we may share parts of our microbiome with the people we live with—including family members, roommates, and romantic partners.They discuss how our microbiomes are shared between people, why romantic partners show particularly high levels of oral microbiome sharing, and whether kissing may be partly responsible. They also explore the surprising connection between the oral and gut microbiomes and what the findings could mean for our health.Dr. Segata and Dr. Eeks also discuss whether some microbes are better at spreading than others, what the research does—and doesn't—tell us about cardiometabolic health, whether probiotics can meaningfully change our microbiome, and how much control we really have over the microbial communities living within us.And if we're sharing our microbiomes with the humans we live with...what about our dogs?About Dr. Nicola Segata: Dr. Nicola Segata is a professor and microbiome researcher at the University of Trento in Italy and a principal investigator at the European Institute of Oncology in Milan. He founded his research laboratory in 2013, bringing together computational scientists, experimental biologists, statisticians, and clinicians to study the human microbiome, its diversity, and how it may influence human health and disease. Work with Eeks? Perhaps you are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to the Eeks Weekly here! (the bits not posted on socia media)Support the show

In this episode, we bring together leaders in oncology, orbital surgery, and ocular pathology to unpack the clinical diagnosis and management of periocular basal cell carcinoma, squamous cell carcinoma, and Merkel cell carcinoma. Our panel walks through how these tumors present and progress, the surgical and reconstructive strategies used to preserve form and function, and the immunotherapy advances reshaping outcomes for advanced and metastatic disease. Whether you're on the front lines of diagnosis or managing complex cases, this conversation offers a multidisciplinary look at where the field stands today.  

P.M. Edition for Aug. 26. Tech reporter Meghan Bobrowsky tells us why the Meta settlement could change how teenagers use some of the world's most popular apps. Plus, the FDA approves a milestone therapy for pancreatic cancer. WSJ reporter Xavier Martinez discusses how the nearly $40,000-a-month drug from Revolution Medicines could change patient outcomes of one the deadliest cancers. And the FBI shuts down a sprawling hacking network linked to China that targeted NASA, the Federal Reserve and critical infrastructure. Sabrina Siddiqui hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

5.04 Jason Arday, Nathan Cofnas and the Decline of University Standards by Plenary Session

In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer Program⁠Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer⁠American Society of Clinical Oncology | Fertility Preservation Guidelines⁠Stupid Cancer⁠Livestrong Foundation⁠Journal of Adolescent and Young Adult Oncology⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when your life changes in an instant, and then, just when you think you're beginning to rebuild, you're faced with another life-altering diagnosis? Shannon Michelle knows that experience firsthand. After a devastating motorcycle accident left her in a coma with a traumatic brain injury, Shannon had to relearn how to walk, read, speak and navigate a life she no longer remembered. Then, during her recovery, she was diagnosed with breast cancer. Today, Shannon joins us to talk about her breast cancer experience, the emotional realities of healing, and how an unimaginable series of events changed the way she sees her life. Key Takeaways Stay present, especially when life feels overwhelming Self-care is essential to recovery Accepting a new reality can be empowering Let go of what you cannot control Give yourself permission to be the best version of yourself today Chapters 00:00 — Surviving a devastating accident 04:30 — A breast cancer diagnosis 07:57 — The PATCH framework for healing 16:50 — Accepting a new reality 23:50 — Letting go of control Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

There are already 700 to 800 FDA-approved AI devices on the market, yet a busy oncologist still has nowhere trustworthy to learn which ones are worth their time.In this episode, Dr. Doug Flora joins us to share how he is closing that trust gap. He is the Executive Medical Director of Oncology at St. Elizabeth's Yung Family Cancer Center and co-founder of Tensor Black, a clinician-led education platform he calls "the GPS for oncology."We discussed the three layers of AI in cancer care, from ambient note-taking to the "co-pilot" that supports physicians, and why detection is moving upstream to the "pre-patient" stage. Dr. Flora unpacks St. Elizabeth's screening program, which has caught roughly 900 stage-one lung cancers across 65,000 patients screened, and why keeping physicians "at the wheel" matters. From a region often called the epicenter of cancer in America, this is a founder using better tools to fight a very local fight.Hosted by Logan JonesMiddle Tech is proudly supported by:KY Innovation → kyinnovation.comAwesome Inc → awesomeinc.org

For over a decade, sorafenib remained unchallenged as first-line therapy for hepatocellular carcinoma, based on the SHARP trial, which showed survival increasing from 7.9 to 10.7 months. This demonstrated modest efficacy in a disease notoriously resistant to systemic treatment. That drought broke in 2020, when IMbrave150 demonstrated that atezolizumab plus bevacizumab beat sorafenib outright, pushing median survival past 19 months and putting immunotherapy on the map for liver cancer. Two years later, HIMALAYA proved that a single priming dose of anti-CTLA-4 could unlock durable responses, with the STRIDE regimen nearly doubling five-year survival compared with sorafenib. Then IMbrave050 asked whether that success could move earlier, into the adjuvant setting after resection — and the early promise didn't hold up on longer follow-up. Together, these three trials mark both immunotherapy's arrival in liver cancer and the limits of assuming it translates cleanly across settings.Trials Discussed on Today's Episode:HIMALAYA TrialIMbrave 050IMbrave 150For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger White provides an in-depth overview of the company's light-activated small-molecule technology and its development for non-muscle-invasive bladder cancer.Roger discusses the company's completed clinical study enrollment, reported response and safety data, planned regulatory submissions to Health Canada and the FDA, and its collaboration with Ferring Pharmaceuticals.Learn more: https://theralase.com/Watch the full YouTube interview here: https://youtu.be/yeFJUx2w9d8And follow us to stay updated: https://www.youtube.com/@stockstowatchofficial 

In this episode, Boris Pasche, MD, PhD, FACP, President and Chief Executive Officer of Barbara Ann Karmanos Cancer Institute and Oncology Department Chair at Wayne State University, joins the podcast to discuss navigating uncertainty in today's healthcare environment. He shares insights on evolving therapy services and highlights emerging breakthroughs in oncology that are shaping the future of cancer care.

This mini-series on Behind the Knife will delve into the technical aspects of the Operative Standards for Cancer Surgery, developed through the American College of Surgeons Cancer Research Program. This third episode highlights the Hepato-Pancreato-Biliary cancer operative standard.Hosts:Eliza W. Beal, MD, FACS (X: @ElizaWBealMD) is a Hepato-Pancreato-Biliary surgeon at the Barbara Ann Karmanos Cancer Institute in Detroit. She is also an associate professor of Oncology and Surgery at Wayne State University School of Medicine.Morgan Jackson, MD is a general surgery resident at the Detroit Medical Center and Wayne State University in Detroit, MI.Daniel Nelson, MD, FACS, FSSO (X: @DWNelsonHPB) is a Hepato-Pancreato-Biliary surgeon at the University of Tennessee Health Science Center - Chattanooga.Hop Sanderson Tran Cao, MD, FACS (X: @HopSTranCao) is a Hepato-Pancreato-Biliary surgeon at MD Anderson Cancer Center. Guest:Alice Wei, MD is a Hepato-Pancreato-Biliary surgeon at Memorial Sloan Kettering and associate professor of surgery at Weill Cornell School of Medicine. Dr. Wei contributed to the development of the operative standards for HPB surgery. Learning Objectives: The goals of this podcast are to provide education about the standards, generate discussion, and offer technical pearls to both oncologic specialists and general surgeons, to all of whom these standards apply. In this podcast we discuss the operative standards for liver resection for hepatocellular carcinoma, which includes that the surgeon should: (1) perform a thorough inspection of the liver and abdomen, either laparoscopically or open, including performing liver ultrasound, and (2) should resect all lesions to macroscopically negative margins, preferably with an anatomic resection. Our guest Dr. Wei also provides technical tips, pearls for improving skills performing and interpreting liver ultrasound, and discusses the role of lymphadenectomy in patients with hepatocellular carcinoma. References: Operative Standards for Cancer Surgery, Volume 3: Sarcoma, Adrenal, Neuroendocrine, Peritoneal, Urothelial, Hepatobiliary https://www.facs.org/quality-programs/cancer-programs/cancer-surgery-standards-program/operative-standards-for-cancer-surgery/purchase/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewOBGYN Oral Board Review Coures: https://behindtheknife.org/course/obgyn-oral-board-reviewEPA Playbook: https://behindtheknife.org/course/epa-playbookSurgical Instrument Flashcards: https://behindtheknife.org/course/surgical-instrument-flashcardsABSITE Review: https://behindtheknife.org/course/absite-2026-exam-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

For decades, traditional cancer treatments like chemotherapy and radiation have targeted tumors directly—often with severe side effects and mixed results. But what if the key to treating cancer was already inside our bodies? Prof. Thomas Gajewski, a renowned oncologist at the University of Chicago, is leading a revolution by using the body's gut microbiome to fight cancer. His pioneering work in cancer immunotherapy focuses on why some patients with melanoma responded dramatically to immune-based therapies while others do not. In this episode, Gajewski discusses how training T-cells to recognize and attack tumors is transforming oncology, why the microbiome might hold the key to supercharging cancer treatments, and what it will take to make life-saving immunotherapies effective for every patient. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | ⁠From Cancer Patient to Cancer Survivor: Lost in Transition⁠National Cancer Institute Office of Cancer Survivorship⁠American Society of Clinical Oncology | Survivorship Compendium⁠CancerCare⁠HopeWell Cancer Support⁠National Coalition for Cancer Survivorship⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Decentralized clinical Trials (DCTs) bring some or all elements of a clinical trial closer to patients. Consent, screening, treatment administration, and more can be administered through digital technologies and local health care providers, expanding accessibility for patients who face barriers to participation in traditional single site trials. In this episode, CANCER BUZZ speaks with Erin Pierce, MSN, APRN, FNP-C, Associate Clinical Investigator and Nurse Practitioner at HonorHealth Research Institute, and Kristen Kipping-Johnsson, MPH, Director of Network Research Operations at the University of Chicago, about how each of their cancer programs are approaching DCT implementation. Their discussion explores how decentralized components, such as community-based treatment delivery, centralized research infrastructure, and hybrid trial designs, can increase participation opportunities for patients in both community and academic settings. Guests: Erin Pierce, MSN, APRN, FNP-C Associate Clinical Investigator Nurse Practitioner HonorHealth Research Institute Scottsdale, AZ   Kristen Kipping-Johnson, MPH Director of Network Research Operations University of Chicago Chicago, IL "APPs are really poised to step into that role [of investigator] and help, not take the place of physicians, but work alongside our physician colleagues and enable us to expand the abilities of research." —Erin Pierce, MSN, APRN, FNP-C "Quality of life, being able to keep patients treated closer to home, allow them to stay with the physician that diagnosed them...Those are the things that are really important to me when it comes to decentralization." —Kristen Kipping-Johnson, MPH Resources HonorHealth Research Institute's First Steps to Approaching Decentralized Clinical Trials (DCTs) University of Chicago's Path to Operationalizing Decentralized Phase 1 Trials Across a Regional Network ACCC's Community Oncology Research Institute White Paper: Bringing Cancer Research to the Community:  Strategic Approaches to Representative Oncology Clinical Trial Design This podcast was created in partnership with the Decentralized Trials & Research Alliance, with support from Eli Lilly and Company, Gilead Sciences, and Merck.

In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer Survivorship⁠Harold P. Freeman Patient Navigation Institute⁠National Cancer Institute Office of Cancer Survivorship⁠Patient Navigator Outreach and Chronic Disease Prevention Act of 2005⁠American Cancer Society⁠Tuskegee Study Timeline | Centers for Disease Control and Prevention⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Ayesha and Andrew discuss the August 19, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Pain Management, Knee, Orthopaedic Essentials, Oncology, Spine, Pediatrics, Trauma Chapters (00:00:02) - JBJS: Cases On Hold(00:01:20) - The Arthroplasty Industry: New Paradigm Shift(00:02:46) - Episode 111, The Case is on Hold(00:03:21) - Interbody Fusion for recurrent lumbar disc herniations(00:05:13) - Probability Score Matching for Interbody Fusion vs Repeat Micro(00:06:23) - Intermodal Fusion vs Microdiscectomy: Controvers(00:12:58) - Interbody Fusion vs Repeat Discectomy: The Decision(00:17:26) - Intraosseous morphine for total knee arthroplasty(00:26:13) - Estimating Acetabular Protrusion Risk in Patients with(00:33:06) - Robinson on the Protrusio Risk Score(00:39:04) - Sarcoma Outcomes of Unplanned Excisions(00:41:14) - Rotating Hinge Total Knee Arthroplasty

Bret Miller was 17 when he first felt a lump behind his nipple. For seven years, providers told him it was calcium buildup or that it would go away on its own. It didn't. At 24, Bret was diagnosed with Stage 1 breast cancer — a disease most people, including many of the doctors he saw along the way, don't associate with men at all.In this episode, Bret joins his oncologist, Dr. Priyanka Sharma of The University of Kansas Cancer Center, to unpack why male breast cancer is so often missed or overlooked by so many health care providers — and why most men have never been told what normal breast tissue looks or feels like for them in the first place. Together, they talk about what needs to change in clinical training and patient conversations, and what self-advocacy looks like when the system isn't built to catch what you're describing. This episode is part of the Komen Health Equity Revolution podcast series, which centers the lived experience of communities too often overlooked in breast cancer awareness and care — including men. 5 Key Takeaways Men need to know the signs and symptoms of breast cancer A persistent change in one breast should be investigated Nipple discharge can be a warning sign of breast cancer Patients should advocate for themselves and seek second opinions Healthcare providers should take concerning breast changes seriously Chapters 03:10 Bret's Seven-Year Journey to a Diagnosis 10:55 Why Male Breast Cancer Gets Missed 15:09 Knowing What Is Normal for Men 17:11 Turning a Diagnosis Into Advocacy 24:39 How Healthcare Providers Can Close the Gap Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Matt Smith, 42, metastatic prostate cancer, Wilmington, NC, with Michael Serzan, Medical Oncologist, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

In this second installment of their conversation on depression in oncology, Daniel C. McFarland, DO, and Boris Kiselev, MD, moved from diagnosis, covered in Part 1, into treatment. The discussion opened with the differential diagnoses that need to be ruled out before starting therapy: delirium, bipolar disorder, medical conditions such as endocrinopathies and severe anemia, and neurocognitive issues stemming from central nervous system involvement or dementia. McFarland and Kiselev outlined the specific red flags that should prompt an oncologist to bring in a mental health specialist rather than manage treatment alone, including suicidality, psychosis, and complex psychiatric histories.From there, the conversation turned to how depression is categorized by severity using the PHQ-9 scale, and how that severity, along with patient preference and access to care, should guide the choice between lifestyle modification, psychotherapy, and pharmacotherapy. Kiselev introduced a simplified 4-drug toolkit for oncologists: 1 selective serotonin reuptake inhibitor, 1 serotonin and norepinephrine reuptake inhibitor, mirtazapine (Remeron), and bupropion, explaining how to match each option to a patient's specific symptoms and adverse effect (AE) concerns.The back half of their discussion served as a practical walkthrough for starting a patient on medication. They covered how to frame the conversation to reduce stigma, what to say about timelines for benefit, and specific dosing and titration guidance for each of the 4 core drugs. McFarland and Kiselev closed by highlighting the most common AEs to flag upfront, a real-world case illustrating why dose titration matters, and general guidance on how long patients typically stay on treatment.McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor in the Psycho-oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in internal medicine.00:02-02:24: Recap of the prior episode and framing for treatment02:24-11:17: Ruling out other causes: delirium, bipolar disorder, medical conditions, and neurocognitive issues11:49-15:17: Deciding when an oncologist can treat directly vs when to refer to a mental health specialist15:45-23:01: Categorizing depression severity with the PHQ-9 and matching it to lifestyle, psychotherapy, or medication23:46-26:05: Choosing between non-pharmacologic and pharmacologic treatment based on severity and access26:05-35:49: Selecting a medication from a core 4-drug toolkit and preparing the patient to start it37:30-48:30: Drug-specific dosing, titration strategy, and managing common adverse effects50:37-51:59: How long patients typically stay on treatment and closing thoughts

Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Until recently, biliary tract cancers were relegated to orphan cancer status: rare cancers such as cholangiocarcinoma and gallbladder cancers. These aggressive malignancies were lumped together, historic trials were small, and patients were stuck with gemcitabine-cisplatin chemotherapy as the only real option, a regimen that hadn't changed for almost a decade. Then two trials cracked the field open. BILCAP, reported in 2019, gave resected patients their first evidence-based reason to take adjuvant capecitabine, pushing median survival from around three years to over four. And in 2022, TOPAZ-1 became the first trial to prove immunotherapy has a place in biliary cancer. Durvalumab was added to standard chemo, and in the latest three-year follow-up, it cut the risk of death by over a quarter. Together, these two trials didn't just add drugs to a protocol; they turned biliary tract cancer from an afterthought into a disease with modern treatment pathways.Trials Discussed on Today's Episode:BILCAPTOPAZ-1For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

"Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about chronic lymphocytic leukemia (CLL) treatment considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), including 45 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to treatment of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 184: Oncologic Emergencies 101: Tumor Lysis Syndrome ONS Voice articles: Fixed-Duration Therapy for CLL May Lower Cardiovascular Risks and Costs Less Than Continuous Treatment Individuals With CLL Face Increased Risk for Skin Cancer Master Hypersensitivity Reactions With These Strategies for Prevention and Management Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) ONS symptom management resources:  Fatigue Prevention of Bleeding Prevention of Infection: General Blood Cancer United: Chronic Lymphocytic Leukemia Treatment CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma Treatments Patient education sheets Acalabrutinib Ibrutinib Pirtobrutinib To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Blood work is a really nice way to evaluate if there is progression of the disease. And we evaluate their blood counts, specifically that complete blood count with a differential. We anticipate an elevated white count, and we anticipate that the absolute lymphocyte count is going to be elevated. That's characteristic of the disease. But what evolves and happens is that those numbers can rapidly change and what we get concerned about is if that white count—and the percentage of the absolute lymphocyte count specifically—starts to increase and double quickly." TS 5:52 "There are some components that help clinicians decide if we expect these things, this cadence of change to happen more readily, or if we feel really comfortable that the biology of the variants contributing to the type of CLL that each patient may have, they may not have that progression as quickly or at all. And so that kind of helps us in that follow-up and cadence. Oftentimes, we're checking blood work every three or six months. Some patients are on an annual interval of visits depending on that active surveillance. I think the other piece is that we have a relatively low threshold when there is a change in symptoms to just recheck those blood tests. It's nice that we can have a pretty readily available blood test to be able to give us a lot of information for these patients." TS 9:45 "When we think about CLL therapy, the old tried and true [treatments] still work: so, rituximab and obinutuzumab. And then we kind of start to think about pathways and the way, the mechanisms of which these treatments are integrated. We think about different pathways of how we can induce cell death, but also what are the potential side effects? What are the potential interactions?" TS 19:35 "I think a lot of this is about really having a clear understanding of the patient's goals and really being able to understand and align. I think we have a lot more data to provide guidance for those patients that really are wanting to know: What is my chance of overall survival? If I do this, does this mean that I don't need to ever be on treatment again? If I do it this way, does it mean that I have to come into clinic every week, or does it mean that I have to come in every week but I'm done? I do one year of treatment, and I don't have to think about treatment for a really long time based on some of these components that we can take into consideration." TS 24:36 "When we think about the B-cell lymphoma 2 (BCL-2) inhibitors, with venetoclax, I think the biggest component we think about is tumor lysis syndrome. It's so effective that these cancer cells release all of those electrolytes, potassium, phosphorus; you can see a rise in the lactate dehydrogenase and uric acid because those cells are breaking down. And so subsequently, that leads us to the consideration of, is the patient's kidney function able to clear it? And so a lot of frequent lab monitoring, a lot of hydration, supportive care with medications like ursodiol or allopurinol to really improve the ability to clear that cellular waste product so that it doesn't cause an oncologic emergency." TS 34:11

A free trip to Paris, a 20% off race code, and an AI cancer companion that only uses vetted medical information - this episode packs in way more than your average morning show. JB and Sandy open with Dixie, who is heading to Paris on a spontaneous three-week trip to see an old flame, and somehow makes the whole thing even more entertaining by getting the full story on the phone. From there, the conversation shifts into something much bigger: Suzanne Stone, president and CEO of Livestrong, joins to explain how the organization is helping people affected by cancer with trusted resources, exercise oncology, fertility preservation, and support for the entire family ecosystem.You'll discover:Why Livestrong has spent nearly 30 years becoming a trusted source in a world full of health misinformationHow Ellis, the first AI-powered cancer survivorship companion, works as a closed-loop tool that only uses vetted informationWhat makes the Run for the Roses on October 18 at Auditorium Shores such a perfect community eventHow listeners can join the JB and Sandy teams and save 20% with the code iHeart26Why this race matters whether you walk, run, show up with family, or just want to support someone impacted by cancerSuzanne shares how Livestrong has evolved from the iconic yellow wristband era into a modern platform designed to answer real questions people have after a cancer diagnosis without the noise, scams, or random internet advice. It's practical, timely, and deeply relevant for anyone who has ever had to figure out what to trust when health gets complicated.Plus, you'll hear the kind of off-the-rails, only-on-morning-radio moments that make JB and Sandy such a fun listen, including the latest local buzz, concert talk, and a Texas-sized dose of personality.Essential listening if you want a smart, funny, and surprisingly meaningful mix of community, cancer support, and local radio chaos.

A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda Waltman⁠The Margins Matter | JAMA⁠The Margins Matter | PubMed⁠Life Science Editors Foundation⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

How can artificial intelligence help our scientists find the hidden patterns in cancer's complex biology? In this episode, host Danielle Mandikian is joined by Anwesha Dey, Distinguished Scientist and Executive Director of AI - Oncology and Cancer Biology, to talk about the new reality of the oncology lab. They explore how teaming up with artificial intelligence allows researchers to challenge long-held assumptions, generate bold hypotheses and design novel molecules at speed. Join us to hear how working alongside AI is accelerating the path to new cancer therapies. Read the full text transcript at www.gene.com/stories/ai-in-oncology

In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer Survivorship⁠National Cancer Institute Office of Cancer Survivorship⁠The New England Journal of Medicine⁠Americans with Disabilities Act (ADA.gov)⁠Library of Congress | Civil Rights History Project⁠White Coat, Clenched Fist by Fitzhugh Mullan⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listen to JCO's Art of Oncology poem, "Forty" by Frantz Berthaud, who is Senior Vice President of Oncology Services at University Medical Center of El Paso. The poem is followed by an interview with Berthaud and host Dr. Mikkael Sekeres. Berthaud discusses grief, survival, and mortality in his poem, which honors his sister's life and battle with cancer. LINK TO FULL TRANSCRIPT

Read the full article at: https://oncdata.com/real-world-evidence-ai-in-oncology Artificial intelligence (AI) is rapidly transforming oncology research, but its impact depends on high-quality data. As researchers increasingly rely on real-world evidence (RWE) to complement clinical trials, ensuring that data is accurate, complete, and transparent has become just as important as developing new AI tools. In this episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Saamir Pasha, Senior Biostatistician at Ontada, about two complementary areas of innovation—the establishment of rigorous frameworks to assess the quality of oncology real-world data, and the exploration into how generative AI can accelerate complex biostatistical workflows while maintaining scientific rigor and regulatory transparency. Together, these efforts illustrate how AI is poised to enhance—not replace—the expertise required to generate reliable evidence in oncology.

Breast cancer treatment has a beginning and an end, but healing is often a much longer journey. Today, we are joined by Katie Wasserman, a remarkable mother of four who shares how trusting her instincts and advocating for herself led to her breast cancer diagnosis. She will talk about navigating treatment decisions, the impact it had on her body, and the physical and emotional healing that continues today into survivorship. From managing the fears that linger after treatment ends to intentionally choosing a life focused on thriving instead of simply surviving, Katie's story is a powerful reminder that no one knows your body better than you do. Key Takeaways Trust your instincts when something feels wrong Self-advocacy can lead to life-saving care Asking for help strengthens recovery Small daily habits support healing and resilience Survivorship is about thriving, not just surviving Chapters 00:00 – Trusting your instincts 05:09 – The power of self-advocacy 07:51 – Recovery, support, and staying active 15:04 – Sharing the journey through Instagram 18:27 – Thriving beyond survivorship Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) Clinical Utility of Capivasertib for HR-Positive mBC (38:09) Mitigation and Management of Gastrointestinal Adverse Events (51:05) Management of Dermatologic Adverse Events (59:58) Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42) Monitoring and Management of Cytopenias (1:21:23) CME information and select publications

Read the full article at: https://oncdata.com/personalizing-cancer-prevention-ai-enhanced-imaging As healthcare increasingly shifts from reactive treatment to proactive prevention, artificial intelligence (AI) is emerging as a powerful tool for identifying disease earlier and personalizing patient care. In this episode of Exploring AI in Oncology, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Dr. Sean Raj, Chief Innovation Officer and Chief Medical Officer at SimonMed, about how AI is transforming cancer detection, risk assessment, and patient education. Their conversation highlights how advanced imaging technologies are helping patients gain earlier insights into their health while empowering clinicians with new tools for preventive care.

Read the full article at: https://oncdata.com/ai-driven-pathological-subtyping-pancreatic-cancer-ashish-manne Artificial intelligence (AI) continues to generate excitement across oncology, but its real-world clinical impact remains inconsistent. In this episode of Exploring AI in Oncology, Dr. Ashish Manne, a Gastrointestinal Medical Oncologist at The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, shares his American Association for Cancer Research (AACR) presentation on AI-driven pathological subtyping in pancreatic cancer and highlights the critical shift that is moving AI from theoretical promise to practical application.

5.03 - 5 red flags, Betting Markets, Covid Czar says lab origin by Plenary Session

In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer Institute⁠National Cancer Act of 1971⁠American Cancer Society⁠Dana-Farber Cancer Institute⁠National Library of Medicine⁠The New England Journal of Medicine⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Death is a topic most of us avoid...until we can't.But what if talking about it early actually gave us more peace, not less? In this episode, Leah sits down with Dr. Susan Abernethy, founder of Mudança Healing, whose path from naturopathic medicine and nonprofit leadership (including Make-A-Wish) led her to become an end-of-life doula.Susan shares how having honest conversations early, especially after a cancer or dementia diagnosis, can ease the pressure of rapid-fire medical decisions, bring clarity to what really matters, and offer real comfort to both patients and the families who love them. We get into the practical side too: the gaps hospice care often leaves behind, the toll caregiving takes on families, and why services like respite matter so much. Susan also walks us through the tools she uses in her workshops—from Death Decks to checklists—to help individuals and organizations get ready for what's ahead, not just legally, but practically and emotionally.This conversation is a gentle reminder: planning for the end isn't morbid. It is an act of care for the people you love.Connect with Susan: www.mudancahealing.comand on Instagram @mudanca_healingResources mentioned in this episode:All There Is with Anderson Cooper https://podcasts.apple.com/us/podcast/all-there-is-with-anderson-cooper/id1643163707Death, End-of-Life, and Dementia Decks https://thedeathdeck.com/collections/shop-all-decksA Good Death by Margaret Rice https://bookshop.org/a/103670/9781911632146Learn more about end-of-life doulas at https://inelda.org/Leave a message and let us know what you liked about the episode!Support the showBecome a member of The Cancer Pod Community! Support the podcast and gain access to exclusive content and more! Join today on Buy Me a Coffee or Patreon.Check out thecancerpod.com! Looking for more information? The website has blogs, merch, and all of the episodes listed by season and category. Shop the Bookshop! The shelves at Bookshop feature books by authors who have been on the show and other fav books.Buy The Cancer Pod merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email info (at) thecancerpod (dot) com Follow @TheCancerPod on social media:InstagramBlueskyFacebookLinkedInYouTube

Season 5 Ep 2 - Anthony Fauci's Diary and Congressional Testimony by Plenary Session

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Tonight on America At Night with McGraw Milhaven, it's another edition of MacFarlane Mondays as investigative journalist and MeidasTouch chief Washington correspondent Scott MacFarlane joins McGraw to break down the latest political developments from the nation's capital, offering insight into the biggest stories shaping Washington. Then, Dr. Cynthia Sears, Professor of Medicine, Oncology, and Molecular Microbiology and Immunology at Johns Hopkins University, discusses the growing Cyclospora outbreak, what Americans should know about the foodborne parasite, and the concerning social media trend known as "parasite maxxing," where some people intentionally expose themselves to parasites based on misleading health claims. Plus, author Joshua Kendall joins the program to discuss his latest book, Trudeau & Doonesbury, exploring the life and legacy of legendary cartoonist Garry Trudeau, the impact of Doonesbury on American politics and culture, and why the comic strip continues to resonate decades after its debut. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

When multiple loved ones are diagnosed with breast cancer within a short period of time, it can leave you wondering if, and when, it might become part of your own story. Megan May knew her family history meant that she was at greater risk of developing breast cancer. She prepared as best she could and underwent regular screenings. However, her diagnosis at age 40 still came as a shock because there are some things that no one can fully prepare you for. Megan is here today to share her story - how a series of family diagnoses prompted her to begin early screening, what it was like to hear the words no one wants to hear, and the physical and emotional challenges that followed. We'll talk about how why giving back through fundraising has become such an important part of her mission and how her family supports each other through it all. Key Takeaways Family history can help identify when earlier screenings are needed Early detection can allow cancer to be caught and treated quickly Supporting someone with cancer starts with simply being present Knowing your normal and getting screened can save lives Chapters 00:00 – Megan's family history with breast cancer 02:20 – Starting early screenings 04:04 – Megan's diagnosis and treatment journey 09:39 – Finding strength through movement and survivorship 14:46 – Supporting family and advocating for early detection Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications

In this episode, Dr. James McGee, Osf Healthcare Cancer Institute, discusses the urgent need to expand cancer prevention and early detection in rural communities while addressing the unique challenges rural providers face. He also shares his perspective on AI in oncology, the growing impact of obesity on cancer care, and emerging innovations that could improve access and reduce the cost of treatment.

"When people with PTSD [post-traumatic stress disorder] get quite avoidant—and that can be expressed in so many different ways—the implications can be really profound. I think an important invitation to oncologists and oncology nurses and primary care providers who care for people battling cancer is let's explore what's underneath these avoidant behaviors. Is it a very practical thing? Or is it that underneath this avoidant behavior is really profound fear?" James C. Jackson, PsyD, research professor at Vanderbilt University Medical Center in Nashville, TN, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about addressing medical trauma in oncology. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 31, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to medical trauma in oncology care. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 421: Medical Trauma in Oncology Episode 287: Tools, Techniques, and Real-World Examples for Difficult Conversations in Cancer Care Episode 264: Stop the Stressors and Improve Your Mental Health as a Nurse ONS Voice articles: Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD [post-traumatic stress disorder] Past Trauma Lowers Hope, QOL, and Coping Ability During Cancer Managing Cancer-Related PTSD Starts With Acknowledgement Moral Injury and Trauma in Nursing Trauma-Informed Care Provides Person-Centered Support for Patients During Deep Distress Clinical Journal of Oncology Nursing articles: How Can a Trauma-Informed Care Approach Be Applied to Patients With Gynecologic Cancer? Psychosocial Barriers to Care: Recognizing and Responding Through a Trauma-Informed Care Approach Oncology Nursing Forum articles: Post-Traumatic Distress and Symptom Experience in Patients With Head and Neck Cancer–Related Tracheostomy and Family Caregivers The Effect of Neuroticism, Fear of Progression, and Self-Efficacy on Post-Traumatic Growth in Patients With Lung Cancer Undergoing Chemotherapy The Relationship Between Colorectal Cancer Survivors' Positive Psychology, Symptom Characteristics, and Prior Trauma During Acute Cancer Survivorship ONS course: Psychosocial Dimensions of Cancer Care™ ONS Huddle Card: Coping Screening tools Clinician-Administered PTSD Scale for DSM-5 [Diagnostic and Statistical Manual of Mental Disorders, 5th edition] (CAPS-5) Hospital Anxiety and Depression Scale Primary Care PTSD Screen for DSM-5 PTSD Checklist for DSM-5 Trauma Screening Questionnaire International Society for Traumatic Stress Studies: Free Resources PESI Reclaiming Your Life From Medical Trauma by James C. Jackson To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "For many people who have been traumatized, if they can avoid it, they will. They may not avoid the annual evaluation that is so hugely consequential—they might not avoid that. But they may well avoid a routine visit for a checkup to their oncologist. They very well may avoid a visit with a psychologist who is wanting them to talk about hard things. They may avoid visiting a friend in the hospital because it reminds them of really upsetting things. So, this issue of adherence and compliance is a really big problem." TS 3:19 "Screening tools for things like PTSD can be very useful. They're quite practical, and they're appropriate to use. I really like something called the Post-Traumatic Stress Disorder Checklist. ... Using it is going to be very straightforward. You're going to want to map it onto a 30-day window, and you're going to employ it with patients. It's a 20-item self-report. It assesses 20 DSM-5 symptoms of PTSD. It's not diagnostic, but if people score in this range of 30, 31, 33, we typically are going to believe that that is very suggestive of significant PTSD." TS 9:17 "One of the things we should be doing all the time is modeling and attempting to normalize this idea of being open about mental health difficulties. When I say modeling, this is a complicated issue. ... I'm very open talking about my own battles with mental health. And in some ways, that invites my patients to do the same. I don't recommend necessarily that a nurse says, 'Oh, by the way, I have PTSD. I'm going to tell you about mine. I want you to tell me about yours.' That's a boundary issue. But I think it does behoove us as clinicians to create a culture as much as we're able, where we can talk about mental health difficulties in a matter-of-fact way, acknowledging that mental health is health. These tools, to me, go a long way in that direction." TS 13:41 "The survivorship process is ongoing. I think a nurse can assist a patient in so many ways longitudinally over time. ... One of those ways is to continue checking on mental health outcomes in patients. Continuing to check on mental health outcomes, continuing to explore them, and continuing to invite patients to talk about things that other people might not be asking about. It's easy for family members to assume, 'Hey, you know, you're cancer free now. You look fine, so you must be fine.' It's very possible that the patients we're talking about are not fine. They're far from fine. For that oncology nurse at a follow-up clinic or in an oncology setting to talk about this, continuing to affirm that it would be okay for patients to struggle, continuing to put this issue on a front burner—I think that's really important." TS 21:17 "I'm aware of nurse-led support groups where nurses can talk very freely about their own challenges, in a safe space. ... Working to build cultures in the context of the intensive care unit, let's say, where we have a lot of patients with cancer that prioritize well-being nurse driven programs. ...  The bottom line is if there is a warning light that is blinking, nurses need to attend to that. And in attending to it, they're going to be more present for their patient. They're going to be better able to support their patient. They're going to be better able to support each other. And I think often, in the culture of nursing and psychology, too, people just put their head down, their shoulder down, and they just plow through in ways that are really counter to their mental health." TS 29:56 "The truth is medical trauma can be well-managed. It's not simple. It's not always intuitive. There are all sorts of caveats with regard to this, but the truth is people with medical trauma can live really rich and meaningful lives. ... So, the default setting, I think, should be not one of pessimism. It should be that people with medical trauma can and do get better. If you are a patient with medical trauma and you are in my purview, until proven differently, I'm going to assume that you can get better too." TS 36:28

Plus: Apple approaches $5 trillion market cap. And AstraZeneca says it's on track to hit its revenue target for 2030. Imani Moise hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join host Myrna Young as she delves into cancer care and treatments with Dr. Rohit Gosain and Dr. Rahul Gisain, the Oncology Brothers, board-certified hematologists and medical oncologists from New York. This episode explores separating medical facts from media hype, understanding complex cancer research, and addressing treatment disparities. Learn about breakthrough treatments, the importance of personalized medicine, and how informed decisions can impact outcomes. Whether you're a patient, caregiver, or healthcare enthusiast, gain valuable insights into navigating the evolving landscape of cancer care.The Oncology Brothers share their professional journey and why they chose to specialize in oncology and hematology. They discuss how fast-evolving cancer treatments are being communicated and documented at medical conferences and highlight the significance of unbiased perspectives when selecting the best treatment options. Myrna and the doctors also emphasize the importance of understanding screening guidelines and genetic mutations for personalized cancer treatment, discussing various cancer advances like targeted therapies and immunotherapy. This episode serves as an enlightening resource for anyone affected by cancer, offering both hope and practical advice.Key Takeaways:The Oncology Brothers emphasize the explosion of cancer research and development, pointing out the annual approval of new treatments, which brings hope despite the challenges of keeping up with this data.Conferences serve as vital platforms for cancer education, yet the reality of financial and bias conflicts in the healthcare industry necessitates informed and independent patient advocacy.Treatment personalization through genetic profiling and understanding patient-specific mutations are pivotal in tackling cancers more effectively and improving patient outcomes.Listeners are encouraged to seek knowledge on the available cancer treatments, understand screening guidelines, and engage in shared decision-making with healthcare providers for optimal cancer care.Despite disparities in healthcare access due to geographical and financial constraints, efforts are ongoing to make cutting-edge cancer treatments more widely available.Timestamp Summary0:00 Welcome & Introduction2:09 Understanding Cancer Education5:20 Conversations Around Cancer Treatments10:14 The Role of Medical Conferences15:09 Recent Advancements in Cancer Treatment24:39 Patient Advocacy and Treatment Questions31:09 Disparities in Cancer Treatment Access42:31 Closing Remarks and ResourcesResources:OncBrothers WebsiteOncBrothers Podcast on YouTube | Spotify | Apple PodcastsSocial Media: @ONCBrothers on X/TwitterSponsors for this Episode SquareSquare brings payments, POS, inventory, staffing, and online sales together in one system – so business owners don't have to juggle a bunch of tools. Right now, listeners can get up to $200 off Square hardware when you sign up at square.com/go/transformQuinceQuince is not just apparel. Quince also offers elevated essentials for your home, from bedding and bath, to kitchen essentials and furniture.Make your summer wardrobe feel easier. Go to Quince.com/tym for free shipping on your order and 365-day returns Link to Transcript https://www.buzzsprout.com/1761155/19533950-oncology-advances-inside-the-latest-breakthroughs-in-cancer-treatment/transcriptSee this video on The Transform Your Mind YouTube Channel https://www.youtube.com/@MyhelpsUs/videosTo see a transcripts of this audio as well as links to all the advertisers on the show page https://myhelps.us/Follow Transform Your Mind on Instagram https://www.instagram.com/myrnamyoung/Follow Transform Your mind on Facebookhttps://www.facebook.com/profile.php?id=100063738390977Please leave a rating and review on iTunes https://podcasts.apple.com/us/podcast/transform-your-mind/id1144973094Feedspot Top 100 Mental Health Podcast For sponsored Brand interviews and sponsorship inquires please visit Partner With The Transform Your Mind Podcast | Myrna Young Life Coach